In this context, BCR-ABL1 tyrosine kinase (TK), which is generated by chromosomal translocation between the ABL1 proto-oncogene of chromosome 9 and the BCR gene of chromosome 22 (Philadelphia chromosome), is a highly attractive molecular target for the development of selective chemotherapeutics for patients with CML [2]. Here, TKT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.